Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatiana Stepanova

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Genes & Development|October 19, 2005
The microtubule plus-end-tracking protein CLIP-170 associates with the spermatid manchette and is essential for spermatogenesisAnna Akhmanova, Anne-Laure Mausset-Bonnefont, Wiggert van Cappellen, et al.
Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Genes & Development|October 19, 2005
The microtubule plus-end-tracking protein CLIP-170 associates with the spermatid manchette and is essential for spermatogenesisAnna Akhmanova, Anne-Laure Mausset-Bonnefont, Wiggert van Cappellen, et al.
Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Pageof 2